

## Registration

\_\_\_\_\_  
First Name Middle Initial

\_\_\_\_\_  
Last Name

MD  DO  Other \_\_\_\_\_

\_\_\_\_\_  
Address

\_\_\_\_\_  
City State Zip

\_\_\_\_\_  
Email Address

\_\_\_\_\_  
Specialty

\_\_\_\_\_  
Daytime Phone

\_\_\_\_\_  
Fax

Indicate any special accommodations or diet required to attend this activity or call Deloris Mercer at (859) 218-0337 to ensure adequate arrangements are made.

## Select Location

- Lexington - Saturday, March 5  
 Hazard - Saturday, April 23

## Registration Fee

There is no registration fee to attend this CME.

## 4 Ways To Register

**Online:** [www.CEcentral.com/live/2781](http://www.CEcentral.com/live/2781)

**Fax** completed form to: (859) 323-2920

**Mail** completed form to:

UK HealthCare CEcentral

Attn: Kim Page

138 Leader Ave, Ste. 9

Lexington, KY 40506-9983

**Call:** (859) 218-0337

## Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine, the Kentucky Office of Drug Control Policy, and the Kentucky Department for Behavioral Health, Developmental and Intellectual Disabilities. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits (TM)*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Statements of credit will indicate credits earned based on participation and will be issued online at the conclusion of the activity. In order to receive CME credit, you will be requested to sign in at registration, attend the entire live CME activity, and request credit online at the conclusion of the activity.

*An Equal Opportunity University*

## Cancellation

The joint sponsors reserve the right to cancel or make substitutions in this activity.

## Endorsements

This educational activity is endorsed by the Kentucky Board of Medical Licensure, the Kentucky Medical Association, and the Kentucky Board of Pharmacy.


## Acknowledgment

This educational activity is supported by an unrestricted education grant from Reckitt Benckiser Pharmaceuticals Inc.

# Buprenorphine Diversion and Misuse

## Decreasing the Risk & Protecting Office-based Buprenorphine Treatment

Lexington - Saturday, March 5, 2011  
or  
Hazard - Saturday, April 23, 2011



### Jointly sponsored by

Kentucky Office of Drug Control Policy

Kentucky Department for Behavioral  
Health, Developmental and  
Intellectual Disabilities



## Activity Description

This educational activity is designed to provide useful and the most up-to-date information about best practices in office-based opioid dependence treatment that minimize risk of buprenorphine diversion and misuse from patients in your practice.

## Target Audience

Physicians who are qualified to prescribe buprenorphine in an office-based setting for the treatment of opioid dependence regardless of whether they are currently prescribing buprenorphine products are encouraged to attend.

## Agenda

8:30 AM	Registration and Breakfast
9:00 AM	<b>The Current Problem of Diversion &amp; Misuse</b>
9:15 AM	<b>Practices to Decrease Diversion &amp; Misuse: Part I</b>
10:15 AM	Break
10:30 AM	<b>Clinically Relevant Pharmacology of Buprenorphine</b>
11:15 AM	<b>Practices to Decrease Diversion &amp; Misuse: Part II</b>
Noon	Lunch Break
12:30 PM	<b>Patient Resources</b>
12:45 PM	<b>Speaker Panel: Audience Questions and Case Discussion of Management of Difficult Patients</b>
1:45 PM	Evaluation and Adjournment

## Learning Objectives

Upon completion of this educational activity, you will be able to:

- Identify and implement specific time- and cost-sensitive office practices that can decrease buprenorphine diversion and misuse
- Discuss the reasons for and types of diversion and misuse
- Discuss the pharmacology of buprenorphine as it relates to dosing, diversion and misuse
- Set limits and work effectively with difficult patients

## Faculty

### Mark S. Jorrisch, MD

Medical Director  
Louisville Metro Public Health and Wellness M.O.R.E. Center  
Louisville, Kentucky

Dr. Jorrisch is a practicing physician in Internal Medicine at Jewish Hospital. He is the Medical Director for the MORE Center, is a consultant for the Kentucky Board of Medical Licensure, and is an Assistant Clinical Professor in Internal Medicine at the University of Louisville School of Medicine. He serves as a Mentor for the Physician Clinical Support System for Buprenorphine for Kentucky.

### Stephen Lamb, MD

Private Practice  
Lexington, Kentucky

Dr. Lamb is a psychiatrist working in the field of opiate dependence since 1991. He is a voluntary assistant professor of psychiatry at the University of Kentucky College of Medicine. He serves as a Mentor for the Physician Clinical Support System for Buprenorphine for Kentucky.

### Michelle Lofwall, MD

Assistant Professor, Psychiatry & Behavioral Science  
University of Kentucky

Dr. Lofwall is an adult psychiatrist specializing in office-based buprenorphine treatment for opioid dependence. Her clinical research is aimed at improving the treatment of prescription opioid dependence. She serves as a Mentor for the Physician Clinical Support System for Buprenorphine for Kentucky and is actively involved in teaching medical students and residents about office-based opioid addiction treatment encouraging all medical specialties to learn more and help treat addiction.

### Michele Flowers McCarthy, LPCC

Program Administrator  
Kentucky Division of Behavioral Health (DBH)

Michele has more than 12 years of experience in the field of substance abuse treatment and is a Licensed Professional Clinical Counselor. She works primarily as the designee for the State Opioid Treatment Authority (SOTA) and oversees the technical assistance and monitoring of Kentucky's 11 Opioid Treatment Programs (OTPs). Michele also works with Kentucky's 14 Community Mental Health Centers (CMHCs) to coordinate monitoring and provide technical assistance.

### Sharon Walsh, PhD

Professor, Psychiatry & Behavioral Science  
Director, Center on Drug and Alcohol Research  
University of Kentucky

Dr. Walsh's research has evaluated clinically relevant pharmacologic aspects of methadone and buprenorphine as well as the abuse liability of prescription opioids. She has served on FDA advisory panels evaluating new tamper resistant drug formulations and has taught doctors about the clinical pharmacology of buprenorphine and other opioids. She is also the past President of the College on Problems of Drug Dependence.

## Disclosure

All planners, speakers, authors, reviewers and staff members involved with content development for continuing education activities sponsored by the University of Kentucky College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.

## Meeting Locations

### Lexington

Bluegrass Regional Mental Health: Bluegrass Prevention

1351 Newtown Pike  
Lexington, KY 40511  
Phone (859) 225-3296

### Hazard

Hazard Community and Technical College

One Community College Drive  
Hazard, KY 41701  
Phone (606) 436-5721

